目的 探討脈君安片聯(lián)合纈沙坦膠囊治療中老年原發(fā)性高血壓的臨床療效。方法 選擇2021年2月—2021年6月在天津市紅橋醫(yī)院治療的102例原發(fā)性高血壓老年患者，根據(jù)用藥的差別分為對照組和治療組，每組各51例。對照組口服纈沙坦膠囊，80 mg/次，1次/d；治療組在對照組基礎(chǔ)上口服脈君安片，1.5 g/次。3次/d。兩組患者均經(jīng)4周治療。觀察兩組患者臨床療效，比較治療前后兩組血壓水平，證候改善時間，及血清單核細(xì)胞趨化蛋白1（MCP-1）、同型半胱氨酸（Hcy）、基質(zhì)金屬蛋白酶-9（MMP-9）、降鈣素基因相關(guān)肽（CGRP）、人可溶性細(xì)胞黏附分子（sICAM-1）和血管性假血友病因子（vWF）水平。結(jié)果 經(jīng)治療，對照組和治療組總有效率分別為84.31%和98.04%，差異有統(tǒng)計學(xué)意義（P<0.05）。經(jīng)治療，兩組SBP（收縮壓）、DBP（舒張壓）較治療前均顯著下降（P<0.05），且治療組改善更明顯（P<0.05）。經(jīng)治療，治療組患者頭暈、頭痛、心煩、耳鳴等癥狀改善時間均早于對照組（P<0.05）。經(jīng)治療，兩組血清MCP-1、Hcy、MMP-9、CGRP、sICAM-1、vWF水平均明顯降低（P<0.05），且治療組下降更顯著（P<0.05）。結(jié)論 脈君安片聯(lián)合纈沙坦膠囊治療中老年原發(fā)性高血壓不僅促進(jìn)血壓下降，還能夠促進(jìn)機(jī)體細(xì)胞因子和臨床癥狀的改善。

Objective To investigate the clinical efficacy of Maijunan Tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension. Methods Patients (102 cases) with essential hypertension in Tianjin Hongqiao Hospital from February 2021 to June 2021 were divided into control and treatment group according to different treatments, and each group had 51 cases. Patients in the control group were po administered with Valsartan Capsules, 80 mg/time, once daily. Patients in the treatment group were po administered with Maijunan Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluation was evaluated, the blood pressure, the improvement time of symptom, and the levels of serological indexes MCP-1, Hcy, MMP-9, CGRP, sICAM-1 and vWF in two groups before and after treatment were compared. Results After treatment, the effective rates of the control group and the treatment group were 84.31% and 98.04%, respectively (P < 0.05). After treatment, the levels of SBP and DBP in two groups were significantly lower than those before treatment (P< 0.05), and the improvement in the treatment group was more obvious (P< 0.05). After treatment, the improvement time of dizziness, headache, annoyance and tinnitus in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the levels of serum MCP-1, Hcy, MMP-9, CGRP, sICAM-1 and vWF were significantly decreased in two groups (P< 0.05), especially in the treatment group (P < 0.05). Conclusion Maijunan Tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension can not only promote the decrease of blood pressure, but also improve the cytokines and clinical symptoms.

R972

天津市科技發(fā)展計劃攻關(guān)項目（SHGY-2018039）